Research outlook

Where EGFR-mutant lung cancer treatment is heading

EGFR-mutant lung cancer · Updated Nov 15, 2026

About 1 in 7 non-small cell lung cancers in the US, and about 4 in 10 in East Asia, carry an EGFR mutation, often in people who never smoked. Daily osimertinib pills are the backbone of treatment, and two stronger first-line options now extend survival: adding chemotherapy (FLAURA2) or switching to amivantamab plus lazertinib (MARIPOSA). Research is focused on what to do when osimertinib stops working, with drug-carrying antibodies (antibody-drug conjugates) leading, and on treating earlier-stage disease around surgery and radiation.

  1. Now

    Nov 2026

    Two stronger first treatmentsHappened 47.5 months median survival

    Osimertinib plus chemo (47.5 vs 37.6 months median survival) and amivantamab plus lazertinib (60% vs 51% alive at 3 years) both beat osimertinib alone.

    47.5: months median survival with osimertinib plus chemo, vs 37.6 alone.

    Drug-carrying antibodies after resistanceHappened 8.3 months without progression

    Sac-TMT and a HER3 antibody-drug conjugate both delayed growth for about 8 months vs 4 to 5 with chemo in Chinese phase 3 trials.

    8.3: months without progression with sac-TMT, vs 4.3 with chemotherapy.

    Osimertinib earlier in the diseaseHappened 39.1 months without progression

    After chemoradiation it delayed progression for 39.1 vs 5.6 months; before surgery it left little cancer behind in 26% vs 2%.

    39.1: months without progression after chemoradiation, vs 5.6 with placebo.

  2. 6 months

    by May 2027

    Dato-DXd after osimertinibLikely

    AstraZeneca's TROPION-Lung15 (768 people) tests Dato-DXd, alone or with osimertinib, against chemotherapy after osimertinib; due January 2027.

    A first pill trial for exon 20Possible

    ArriVent's FURVENT (398 people) compares firmonertinib with chemotherapy for exon 20 insertions; its main analysis was due October 2026.

  3. 12 months

    by Nov 2027

    Sac-TMT tested worldwidePossible 8.3 months without progression (China)

    Merck's global trial (556 people) compares sac-TMT with chemotherapy in previously treated disease; due May 2027.

    8.3: months without progression with sac-TMT in China, vs 4.3 with chemotherapy.

    Osimertinib for very early cancerPossible

    AstraZeneca's ADAURA2 (390 people) tests osimertinib after surgery for stage IA2 to IB tumors; due August 2027.

    Zipalertinib plus chemo firstPossible 35.2% tumors shrank (later line)

    Taiho's REZILIENT3 (285 people) adds zipalertinib to first-line chemotherapy for exon 20 insertions; due May 2027.

    35.2%: of exon 20 tumors shrank on zipalertinib alone.

  4. 3 years

    by late 2029

    An antibody-drug conjugate in first linePossible

    TROPION-Lung14 (582 people) adds Dato-DXd to first-line osimertinib; due March 2028. A win could change first treatment again.

    Iza-bren against chemotherapyPossible 47.4% tumors shrank (early trials)

    Bristol Myers Squibb's IZABRIGHT-Lung01 (661 people) is due December 2028.

    47.4%: of tumors shrank in early trials.

  5. 5 years

    by late 2031

    Pills after surgery for rarer mutationsPossible

    Zipalertinib (REZILIENT4) and sunvozertinib trials test post-surgery treatment for exon 20 and other uncommon mutations; due 2029.

    Personalized first-line choicesLong shot 60% alive at 3 years

    With several first-line combinations available, trials aim to match treatment to risk, for example by mutation type and brain metastases.

    60%: alive at 3 years with amivantamab plus lazertinib, vs 51%.

Happened Likely Possible Long shot

The research paths

Heating up

Antibody-drug conjugates

8.3 months without progression
Details and 6 trialsHide
Maturing

Stronger first-line combinations

47.5 months median survival
Details and 1 trialsHide

Adding chemotherapy or amivantamab up front to delay resistance, and learning who needs the extra side effects.

WatchLonger follow-up and quality-of-life data.

Active

Earlier-stage treatment

26% major pathologic response
Details and 3 trialsHide
Active

Uncommon mutations

35.2% tumors shrank
Details and 3 trialsHide

Borrowed from other cancers

From Breast cancer

Datopotamab deruxtecan (Dato-DXd)

Phase 3

A TROP2 antibody-drug conjugate first approved for HR-positive breast cancer; now approved for previously treated EGFR-mutated lung cancer and in first-line trials.

From Breast cancer

Sacituzumab tirumotecan

Phase 3

A TROP2 antibody-drug conjugate also being tested in triple-negative and HR-positive breast cancer.

From Other lung cancers

Ivonescimab

Phase 3

A PD-1 and VEGF bispecific antibody tested across non-small cell lung cancer.

Open to join now

See every recruiting EGFR lung cancer trial →

When the trials finish

Completion dates the trials registered. Results usually follow 3 to 12 months later.

2026202720282029203020312032Today
Sac-TMT vs chemotherapy, later linesAntibody-drug conjugates
May 2027
Aug 2027
Aug 2028
Dec 2028
Feb 2029
Amivantamab combinations, first lineStronger first-line combinations
May 2029
Sep 2029
Oct 2029
Sep 2030

What just happened

HER3 antibody-drug conjugate beats chemotherapy after EGFR pills

HERON-Lung01, The Lancet.

Ivonescimab delays progression; survival gain not significant globally

HARMONi, Lancet Oncology.

Osimertinib plus chemo extends survival

FLAURA2, NEJM.

Sac-TMT extends survival after resistance

OptiTROP-Lung04, NEJM.

Standard treatment today

How to read this page, and sourcesHow to read this page, and sources

See EGFR lung cancer trials recruiting now →

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.